Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027

Eton Pharmaceuticals and Aquestive Therapeutics have entered into an exclusive U.S. license and supply agreement for LIBERVANT, a buccal film for treating seizure clusters in epilepsy patients, with commercial availability expected in April 2027, pending FDA approval. The buccal film addresses a market opportunity exceeding $450 million annually in the U.S., with patient research indicating a strong preference for this form over nasal spray. LIBERVANT has received Orphan Drug Designation and is protected by patents extending to 2038, with additional applications pending.